In July 2018 it was announced that Keranetics would merge with Lexington MA based firm - MicroChip Biotech - to form a new firm called Keratin Biosciences. Inc. Continuing to operate in both locations, Keratin Biosciences is strucured to advance both regenerative medicine and drug delivery therapies, based on a purified human-derived keratin technology platform. The company aims to bring transformative new products to market that promote regenerative healing of complex tissue injuries and skin wounds and conditions. KeraNetics, LLC, - the orginal SBIR Involved firm - a biomaterials company spun out of Wake Forest Institute of Regernerative Medicine, develops and manufactures keratin-based products for use in therapeutic and regenerative medical applications. The firm's keratin-based biomaterials is used for burn management, hemostasis, hemorrhage resuscitation, nerve repair and regeneration, muscle and bone repair and regeneration, and drug delivery. The company also provides hydrogel wound dressing for burn management that controls burn wound progression; keratin-based hemostatic biomaterial, which is used in wound management as a bandage; hemorrhage resuscitation biocompatible system that is used in the treatment for victims of hemorrhage and shock without the potential for tissue damage or thrombotic events; biomaterials that supports bone repair and regeneration in healthy and osteoporotic bone; biocompatible delivery vehicles that provide a structural matrix for cell attachment; and tissue-specific drug delivery solutions. KeraNetics, LLC was formerly known as KeraMedica, LLC.
